Citigroup
CATX icon

Citigroup’s Perspective Therapeutics CATX Stock Holding History

Citigroup’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$885K Buy
212,131
+137,090
+183% +$579K ﹤0.01% 3197
2025
Q4 		$206K Sell
75,041
-50,267
-40% -$143K ﹤0.01% 3991
2025
Q3 		$430K Buy
125,308
+28,758
+30% +$105K ﹤0.01% 3652
2025
Q2 		$332K Buy
96,550
+56,210
+139% +$148K ﹤0.01% 3838
2025
Q1 		$85.9K Sell
40,340
-4,901
-11% -$14.7K ﹤0.01% 4680
2024
Q4 		$144K Buy
45,241
+6,174
+16% +$50.4K ﹤0.01% 4633
2024
Q3 		$522K Buy
39,067
+28,762
+279% +$383K ﹤0.01% 3699
2024
Q2 		$103K Sell
10,305
-93,229
-90% -$1.35M ﹤0.01% 4197
2024
Q1 		$1.23M Buy
+103,534
New +$883K ﹤0.01% 2861
2021
Q3 		– Sell
-20
Closed – – 5798
2021
Q2 		$0 Hold
20
– – ﹤0.01% 6144
2021
Q1 		$0 Buy
+20
New +$302 ﹤0.01% 6353
2015
Q4 		– Sell
-50
Closed -$1K – 7575
2015
Q3 		$1K Buy
+50
New +$722 ﹤0.01% 7137
2014
Q1 		– Sell
-300
Closed -$2K – 7014
2013
Q4 		$2K Hold
300
– – ﹤0.01% 6770
2013
Q3 		$2K Buy
+300
New +$1.87K ﹤0.01% 6576

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's CATX Position: Q1 2026 in Review

Citigroup increased its Perspective Therapeutics (CATX) stake by 183% in Q1 2026, buying an estimated $579K and bringing the position to 212,131 shares worth $885K. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

Citigroup first reported a position in CATX in Q3 2013 and has held it in 14 quarters since. The position peaked at $1.23M in Q1 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Citigroup held 212,131 shares of Perspective Therapeutics worth $885K as of Q1 2026.
  • Citigroup bought 137,090 Perspective Therapeutics shares in Q1 2026, an estimated $579K.
  • Perspective Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3197 holding.
  • Citigroup first reported a position in Perspective Therapeutics in Q3 2013 and has held it in 14 quarters since.
  • Citigroup's Perspective Therapeutics position peaked at $1.23M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.